Drug intelligence / Profile preview

hypofractionated radiotherapy + GM-CSF + pomalidomide + glofitamab

Development stage: Unknown
Lead developer: First Affiliated Hospital of Xiamen University
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous, Oral, Subcutaneous

Overview

This investigational combination regimen consists of hypofractionated radiotherapy, granulocyte-macrophage colony-stimulating factor (GM-CSF), pomalidomide, and glofitamab. It is currently being evaluated in a Phase 2 clinical trial for the treatment of newly diagnosed primary central nervous system diffuse large B-cell lymphoma (PCNSL DLBCL). The regimen aims to combine the immunogenic cell death induced by radiation with the immunostimulatory effects of GM-CSF, the immunomodulatory properties of pomalidomide (a cereblon E3 ligase modulator), and the T-cell redirecting activity of glofitamab (a CD20xCD3 bispecific antibody). This multi-modal approach is designed to leverage synergistic immune activation to overcome the aggressive nature and immune-privileged environment of CNS lymphomas.

Other names: Hypofractionated Radiotherapy + GM-CSF + Pomalidomide + Glofitamab

Targets

CD3 (T-cell surface glycoprotein CD3)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)

Beyond the preview

Go deeper on hypofractionated radiotherapy + GM-CSF + pomalidomide + glofitamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hypofractionated radiotherapy + GM-CSF + pomalidomide + glofitamab.

Explore the full profile